Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
PHILADELPHIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune disease, including type 1 diabetes, and other severe diseases where engineered iPSCs have the unique potential to transform patients’ lives, today reported financial results for the third quarter ended September 30, 2026, and recent business highlights.